NIFTY 50

Cipla settles patent litigation for cancer drug Revlimid with Celgene in US

Updated : December 14, 2020 01:21 PM IST

Revlimid, which is used to treat conditions such as multiple myeloma, is an approximately $8 billion brand in the US.
Natco Pharma, Dr Reddy’s Laboratories and Alvogen have already settled on the drug.
Like others, Cipla will sell a limited amount of volume of the drug until January 2026 after which there will be no volume caps.

You May Also Like

Live TV

recommended for you